Intra-ovarian injection of platelet-rich plasma in patients with poor ovarian response; a randomized controlled clinical trial [0.03%]
富血小板血浆卵巢内注射治疗卵巢反应低下的患者；一项随机对照临床试验
Azar Yahyaei,Tahereh Madani,Firoozeh Ahmadi et al.
Azar Yahyaei et al.
Ovarian leiomyoma revisited: a retrospective study of 18 cases with diagnostic and therapeutic implications [0.03%]
卵巢平滑肌瘤的再思考：18例回顾性分析及其诊断和治疗意义
Wei Qi,Zhenna Wang,Xi Xie et al.
Wei Qi et al.
Norepinephrine triggers ovarian granulosa cell ferroptosis via α1 receptor-mediated FDXR suppression [0.03%]
去甲肾上腺素通过α1受体抑制FDXR诱导卵巢颗粒细胞铁死亡
Hanqing Hong,Junyan Sun,Lichun Weng et al.
Hanqing Hong et al.
Plasma cell-free DNA 5-hydroxymethylcytosine signatures as predictive biomarkers for platinum resistance and prognosis in epithelial ovarian cancer [0.03%]
用于预测上皮性卵巢癌铂耐药和预后的游离DNA 5-羟甲基胞嘧啶标志物
Yuan Xue,Lei Zhang,Xianglong Chen et al.
Yuan Xue et al.
The stromal microenvironment of ovary: a novel area in polycystic ovary syndrome [0.03%]
卵巢皮质微环境：多囊卵巢综合征研究的新领域
Haichang Wang,Huiqin Zhou,Zhi Liu et al.
Haichang Wang et al.
Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure [0.03%]
妇科肿瘤的化疗耐药：机制见解和克服药物失败的新平台
Pankaj Garg,Ravi Salgia,Sharad S Singhal
Pankaj Garg
The most difficult hurdles associated with the treatment of gynecologic cancer (such as ovarian, cervical, and endometrial cancer) is chemoresistance, with ovarian cancer representing the most clinically challenging subtype due to frequent ...
The immunogenetic basis of ovarian apoptosis: from TNF-α polymorphisms and signaling pathways to glucocorticoid-mediated rescue [0.03%]
卵巢细胞凋亡的免疫遗传学基础：从TNF-α多态性和信号通路到糖皮质激素介导的拯救作用
Farzaneh Motafeghi,Parham Mortazavi,Nasrin Ghassemi Barghi
Farzaneh Motafeghi
Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers [0.03%]
晚期卵巢癌、输卵管癌和原发性腹膜癌化疗前后的同源重组状态的动态变化
Akemi Morimoto,Takashi Matsumoto,Norifumi Teramoto et al.
Akemi Morimoto et al.
Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer [0.03%]
用于铂耐药性卵巢癌的白蛋白结合型紫杉醇联合或不联合拉科替尼的 cost-effectiveness 分析
Shubin Lai,Shufei Lai,Xiaoxin Xu et al.
Shubin Lai et al.
Development of a surface plasmon resonance sensor for assessing infertility based on Anti-Mullerian hormone levels [0.03%]
基于抗穆勒管激素水平的不孕症评估型表面等离子体共振传感器的研发
Hamed Mirshekari,Fatemeh Sabzalizadeh,Ramezan Ali Taheri et al.
Hamed Mirshekari et al.